Ask AI

EU Expert Think Tank: Global Perspectives and Clinical Resources to Optimize Antibody–Drug Conjugate Therapies in Metastatic Breast Cancer

Increase your confidence in the use of antibody–drug conjugates for patients with HR-positive/HER2-negative or triple-negative metastatic breast cancer by reviewing the latest clinical trial data, current treatment guidelines, and toxicity management through certified micro-text modules, downloadable slides, and a ClinicalThought expert commentary.

Share

Program Content

Activities

ADCs in HR Pos HER2 Neg or TNBC
EU Expert Think Tank: Global Perspectives and Clinical Resources to Optimize Antibody–Drug Conjugate Therapies in Metastatic HR-Positive/HER2-Negative or TNBC 
Video
Congratulations: You achieved a completion on 04/09/2022

Released: August 13, 2026

Expires: February 12, 2027

Activities

TROP2 ADCs in Breast Cancer
TROP2 ADCs for Advanced HR-Positive/HER2-Negative and Triple-Negative Cancers: Translating New Data into Practice
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 25, 2026

Les ADCs TROP2 dans le cancer du sein
Anticorps conjugués à des médicaments (ADC) TROP2 pour les cancers avancés HR-positifs/HER2-négatifs et triple-négatifs : Mettre les nouvelles données en pratique
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 09, 2026

ADC dirigidos contra TROP2 en el cáncer de mama
Conjugados anticuerpo-fármaco (ADC) dirigidos a TROP2 en cáncer de mama avanzado RH positivo/ HER2 negativo y triple negativo: cómo trasladar los nuevos datos a la práctica
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2026

ADC anti-TROP2 nel carcinoma mammario
ADC anti-TROP2 nei tumori avanzati HR-positivi/HER2-negativi e triplo-negativi: dalla nuova evidenza alla pratica clinica
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 23, 2026

TROP2-ADCs beim Mammakarzinom
TROP2-ADCs für fortgeschrittene HR-positive/HER2-negative und dreifach negative Krebserkrankungen: Neue Daten in die Praxis umsetzen
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.